Adocia Overview

  • Year Founded
  • 2005

Year Founded

  • Status
  • Public

  • Employees
  • 80

Employees

  • Stock Symbol
  • ADOC

Stock Symbol

  • Share Price
  • $3.88
  • (As of Thursday Closing)

Adocia General Information

Description

Adocia is a clinical-stage biotechnology company focused on developing treatments for diabetes, obesity, and related metabolic diseases. The company uses its proprietary BioChaperone, AdoShell, AdOral and AdoXLong technology platforms to develop improved formulations of therapeutic proteins and peptides, oral and long-acting metabolic treatments, and immunoprotective cell-therapy solutions. Its pipeline includes BioChaperone Lispro, BioChaperone GLP-1 Amylin, AdoXLong Sema, AdOral Sema, AdoShell Islets and M1Pram.

Contact Information

Website
www.adocia.com
Formerly Known As
Proteins & Peptides Management
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 115 Avenue Lacassagne
  • 69003 Lyon
  • France
+33 04
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Pharmaceuticals
Stock Exchange
PAR
Vertical(s)
Corporate Office
  • 115 Avenue Lacassagne
  • 69003 Lyon
  • France
+33 04

Adocia Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Adocia Stock Performance

As of 19-Nov-2026, Adocia’s stock price is $3.88. Its current market cap is $87.7M with 22.6M shares.

(As of Thursday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$3.88 $3.88 $2.25 - $9.92 $87.7M 22.6M 333K -$0.89

Adocia Financials Summary

As of 30-Jun-2026, Adocia has a trailing 12-month revenue of $568K.

In Thousands,
USD
TTM 30-Jun-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 83,938 158,093 99,691 197,717
Revenue 568 1,664 10,086 2,326
EBITDA (16,846) (17,354) (7,505) (21,031)
Net Income (18,543) (18,715) (10,086) (22,899)
Total Assets 24,483 33,423 28,115 27,586
Total Debt 9,180 10,456 8,918 12,459
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Adocia Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Adocia‘s full profile, request access.

Request a free trial

Adocia Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Adocia is a clinical-stage biotechnology company focused on developing treatments for diabetes, obesity, and related met
Biotechnology
Lyon, France
80 As of 2026

New York, NY
 

Cambridge, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Adocia Competitors (66)

One of Adocia’s 66 competitors is Roivant Sciences, a Formerly PE-Backed company based in New York, NY.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Roivant Sciences Formerly PE-Backed New York, NY
Alnylam Pharmaceuticals Formerly VC-backed Cambridge, MA
Dicerna Pharmaceuticals Formerly VC-backed Lexington, MA
Denovo Biopharma Venture Capital-Backed Hangzhou, China
Incyte Formerly VC-backed Wilmington, DE
You’re viewing 5 of 66 competitors. Get the full list »

Adocia Patents

Adocia Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-12544349-B1 Compositions comprising pemvidutide and an acylated amino acid Active 30-Dec-2024
EP-4721760-A1 Composition comprising a peptide having an isoelectric point of less than 6.5 and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals Pending 07-Oct-2024
EP-4721761-A1 Composition comprising semaglutide, cagrilintide and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals Pending 07-Oct-2024
EP-4684802-A1 Composition comprising a peptide having an isoelectric point of less than 6.5 and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals Pending 23-Jul-2024
EP-4684801-A1 Composition comprising semaglutide, cagrilintide and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals Pending 23-Jul-2024 A61K9/0019
To view Adocia’s complete patent history, request access »

Adocia Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Adocia Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Adocia‘s full profile, request access.

Request a free trial

Adocia ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Biotechnology

Subindustry

Rank

Percentile

To view Adocia’s complete esg history, request access »

Adocia FAQs

  • When was Adocia founded?

    Adocia was founded in 2005.

  • Where is Adocia headquartered?

    Adocia is headquartered in Lyon, France.

  • What is the size of Adocia?

    Adocia has 80 total employees.

  • What industry is Adocia in?

    Adocia’s primary industry is Biotechnology.

  • Is Adocia a private or public company?

    Adocia is a Public company.

  • What is Adocia’s stock symbol?

    The ticker symbol for Adocia is ADOC.

  • What is the current stock price of Adocia?

    As of 19-Nov-2026 the stock price of Adocia is $3.88.

  • What is the current market cap of Adocia?

    The current market capitalization of Adocia is $87.7M.

  • What is Adocia’s current revenue?

    The trailing twelve month revenue for Adocia is $568K.

  • Who are Adocia’s competitors?

    Roivant Sciences, Alnylam Pharmaceuticals, Dicerna Pharmaceuticals, Denovo Biopharma, and Incyte are some of the 66 competitors of Adocia.

  • What is Adocia’s annual earnings per share (EPS)?

    Adocia’s EPS for 12 months was -$0.89.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process